All investors are looking for “value”, but this can be far from easy to find. One approach is to look carefully at individual stocks. Often opportunity is hidden within a complex story where high-quality sections of a business are overlooked, leaving the shares trading below a “sum-of-the-parts” value. Combine this with a strong market position that will attract potential buyers and you can have confidence in finding value regardless of the market environment. Some of our investments at Odyssean excite us for exactly these reasons.
Chemring: the value in cybersecurity
Chemring (LSE: CHG) is a leading provider of countermeasures, sensors and energetics products, used mainly by the defence industry. Chemring has a strong record, but we still see significant value in the group. A cybersecurity consultancy called Roke sits within its sensors unit. Roke has world-leading intellectual property and supports governments and companies in high-end cyber and electronic defence missions. Roke is delivering around £80m a year in revenues, is growing at double digits, and enjoys high profit margins. Based on cyber-focused peers, we believe Roke could be valued at four times its revenues (at least) were it a standalone company. This supports a significant portion of Chemring’s current share price – excluding Roke, the rest of the group trades on less than 1.5 times sales. With significant interest in the sector, and recent deals done at two times sales or more, the market seems to be undervaluing the sum of Chemring’s parts.
Euromoney: Covid-19 comeback story
Euromoney (LSE: ERM) is a leading business-to-business provider of data and events services. A complex group with a wide service range, it has significant recurring revenue and looks well placed to see a recovery in “in-person” events as post-Covid-19 reopening continues. We believe the market is overlooking the significant value of the group’s Fastmarkets business, which provides unique pricing data on a variety of commodity markets. This is a high-recurring revenue, high-growth business unit in a market where strategic buyers and private equity are highly active. Informa’s recently announced sale of its intelligence division will provide a relevant reference valuation point for Fastmarkets. Note also that historically, deals have been done at 20 times earnings before interest, tax, depreciation and amortisation (Ebitda) or more. Euromoney as a whole currently trades at around 11 times Ebitda, suggesting overlooked value.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Wilmington: hidden value in training
Wilmington (LSE: WIL) provides training and information services focused on the governance, risk and compliance needs of various markets. The new management team is refocusing and improving the business, which is well placed to benefit from the Covid-19 reopening. It operates a number of business units and brands across a range of markets, with the risk that its complexity is obscuring the value here. For example, Wilmington recently sold its loss-making training business AMT for £23m to a strategic buyer who valued its unique content and market position. We believe similarly overlooked strategic value exists in some of the group’s other business units. With a net cash balance sheet, high revenue visibility and strong cash flow, the sum-of-the-parts value of the group appears underappreciated.
-
Dividend heroes: the investment trusts that have increased their dividends for 20+ yearsInvestment trusts can be a good option for income-focused investors – but which trusts have consistently increased their dividends over the past 20 years?
-
Six reasons not to top up your state pensionA deadline to buy National Insurance credits and top up your state pension is fast approaching. Here’s why it may not be worth it for some people
-
Cash in on the growth prospects of Europe's companiesOpinion Marcel Stötzel, co-portfolio manager of the Fidelity European Trust, selects three stocks
-
Why CEOs deserve a pay riseOpinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
-
Rolls-Royce stock jumps 15% – could it climb further?Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
-
The power of private marketsInterview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success
-
Global investors have overlooked these top tips in emerging marketsOpinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
-
King Coal has not been dethroned yet — should you buy?The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
-
It’s time to start buying Europe again, says Merryn Somerset WebbOpinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
